Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Tumor Biomarker Test Market Status and Forecast (2016-2027)
  • 1.3.2 Global Tumor Biomarker Test Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Tumor Biomarker Test Supply by Company

• 2.1 Global Tumor Biomarker Test Sales Value by Company
• 2.2 Tumor Biomarker Test Sales Area of Main Manufacturers
• 2.3 Trend of Concentration Rate

3 Global and Regional Tumor Biomarker Test Market Status by Category

• 3.1 Tumor Biomarker Test Category Introduction
  • 3.1.1 Prostate Specific Antigen Tests
  • 3.1.2 CTC Tests
  • 3.1.3 Alpha-Fetoprotein (AFP) Tests
  • 3.1.4 CA Test
  • 3.1.5 HER2 Tests
  • 3.1.6 BRCA Test
  • 3.1.7 Anaplastic Lymphoma Kinase (ALK) Tests
  • 3.1.8 EGFR Mutation Tests
  • 3.1.9 KRAS Test
  • 3.1.10 Others
• 3.2 Global Tumor Biomarker Test Market by Category
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional Tumor Biomarker Test Market Status by End User/Segment

• 4.1 Tumor Biomarker Test Segment by End User/Segment
  • 4.1.1 Lung cancer
  • 4.1.2 Breast cancer
  • 4.1.3 Colorectal
  • 4.1.4 Prostate Cancer
  • 4.1.5 Blood Cancer
• 4.2 Global Tumor Biomarker Test Market by End User/Segment
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global Tumor Biomarker Test Market Status by Region

• 5.1 Global Tumor Biomarker Test Market by Region
• 5.2 North America Tumor Biomarker Test Market Status
• 5.3 Europe Tumor Biomarker Test Market Status
• 5.4 Asia Pacific Tumor Biomarker Test Market Status
• 5.5 Central & South America Tumor Biomarker Test Market Status
• 5.6 Middle East & Africa Tumor Biomarker Test Market Status

6 North America Tumor Biomarker Test Market Status

• 6.1 North America Tumor Biomarker Test Market by Country
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Tumor Biomarker Test Market Status

• 7.1 Europe Tumor Biomarker Test Market by Country
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Tumor Biomarker Test Market Status

• 8.1 Asia Pacific Tumor Biomarker Test Market by Country
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Tumor Biomarker Test Market Status

• 9.1 Central & South America Tumor Biomarker Test Market by Country
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Tumor Biomarker Test Market Status

• 10.1 Middle East & Africa Tumor Biomarker Test Market by Country
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Major Downstream Customers Analysis

• 11.1 Customer One Analysis
• 11.2 Customer Two Analysis
• 11.3 Customer Three Analysis
• 11.4 Customer Four Analysis

12 Global Tumor Biomarker Test Market Forecast by Category and by End User/Segment

• 12.1 Global Tumor Biomarker Test Sales Value Forecast (2022-2027)
• 12.2 Global Tumor Biomarker Test Forecast by Category
• 12.3 Global Tumor Biomarker Test Forecast by End User/Segment

13 Global Tumor Biomarker Test Market Forecast by Region/Country

• 13.1 Global Tumor Biomarker Test Market Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 NanoString Technologies Inc.
  • 14.1.1 Company Information
  • 14.1.2 Tumor Biomarker Test Product Introduction
  • 14.1.3 NanoString Technologies Inc. Tumor Biomarker Test Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 Myriad Genetics Inc.
  • 14.2.1 Company Information
  • 14.2.2 Tumor Biomarker Test Product Introduction
  • 14.2.3 Myriad Genetics Inc. Tumor Biomarker Test Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 Luminex Corporation
  • 14.3.1 Company Information
  • 14.3.2 Tumor Biomarker Test Product Introduction
  • 14.3.3 Luminex Corporation Tumor Biomarker Test Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 LabCorp Of America Holdings
  • 14.4.1 Company Information
  • 14.4.2 Tumor Biomarker Test Product Introduction
  • 14.4.3 LabCorp Of America Holdings Tumor Biomarker Test Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 Illumina Inc.
  • 14.5.1 Company Information
  • 14.5.2 Tumor Biomarker Test Product Introduction
  • 14.5.3 Illumina Inc. Tumor Biomarker Test Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Foundation Medicine Inc.
  • 14.6.1 Company Information
  • 14.6.2 Tumor Biomarker Test Product Introduction
  • 14.6.3 Foundation Medicine Inc. Tumor Biomarker Test Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 Danaher Corporation
  • 14.7.1 Company Information
  • 14.7.2 Tumor Biomarker Test Product Introduction
  • 14.7.3 Danaher Corporation Tumor Biomarker Test Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.7.4 SWOT Analysis
• 14.8 Cancer Genetics Inc.
  • 14.8.1 Company Information
  • 14.8.2 Tumor Biomarker Test Product Introduction
  • 14.8.3 Cancer Genetics Inc. Tumor Biomarker Test Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.8.4 SWOT Analysis
• 14.9 Biocept Inc.
  • 14.9.1 Company Information
  • 14.9.2 Tumor Biomarker Test Product Introduction
  • 14.9.3 Biocept Inc. Tumor Biomarker Test Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.9.4 SWOT Analysis
• 14.10 Becton Dickinson & Co.
  • 14.10.1 Company Information
  • 14.10.2 Tumor Biomarker Test Product Introduction
  • 14.10.3 Becton Dickinson & Co. Tumor Biomarker Test Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.10.4 SWOT Analysis
• 14.11 AstraZeneca
• 14.12 Agilent Technologies
• 14.13 Abbott Laboratories, Inc.

15 Conclusion

16 Methodology

Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Tumor Biomarker Test market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Tumor Biomarker Test market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

Segmented by Category
Prostate Specific Antigen Tests
CTC Tests
Alpha-Fetoprotein (AFP) Tests
CA Test
HER2 Tests
BRCA Test
Anaplastic Lymphoma Kinase (ALK) Tests
EGFR Mutation Tests
KRAS Test

Segmented by End User/Segment
Lung cancer
Breast cancer
Colorectal
Prostate Cancer
Blood Cancer

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
NanoString Technologies Inc.
Myriad Genetics Inc.
Luminex Corporation
LabCorp Of America Holdings
Illumina Inc.
Foundation Medicine Inc.
Danaher Corporation
Cancer Genetics Inc.
Biocept Inc.
Becton Dickinson & Co.
AstraZeneca
Agilent Technologies
Abbott Laboratories, Inc.